PEG-MGF

PEG-MGF refers to pegylated mechano growth factor, a variant of IGF-1 that is discussed in experimental muscle and recovery contexts.

It is not a standard therapy in mainstream endocrinology or sports medicine guidelines.

Mechano growth factor is an IGF-1 splice variant associated with mechanical loading in muscle. Pegylation (attachment of a PEG chain) is intended to prolong circulation time and modify distribution.

Use of PEG-MGF is mostly described in non-regulated performance and recovery discussions. It is not indicated for routine treatment of muscle injury or endocrine disorders.

Robust human safety data are lacking.

PEG-MGF (Pegylated Mechano Growth Factor) has a longer half-life than standard MGF, allowing for systemic activity.

PEG-MGF is a conjugate, so two separate things determine what is in the vial: the peptide and the polymer.

• The peptide is the same 24-amino-acid C-terminal E-peptide described on the MGF page — a fragment left over when mature IGF-1 is cut out of its precursor (Fornaro et al., Am J Physiol Endocrinol Metab 2014).

• The PEG chain can vary in molecular weight, in branching, and in which residue it is attached to. For approved PEGylated medicines those parameters are fixed and stated on the label, because they determine clearance, distribution and immunogenicity (Veronese & Pasut, Drug Discov Today 2005). For research-catalog PEG-MGF none of them are disclosed, so two vials with the same name need not be the same compound.

Analysis of black-market MGF products found they were not human MGF at all but C-terminally amidated analogues (Esposito et al., Rapid Commun Mass Spectrom 2012). There is no comparable published analysis of what is sold as PEG-MGF, and no pharmacopeial monograph or reference standard exists against which a buyer could check.

Evidence is limited to preclinical work and small-scale or informal human use reports; high-quality randomized data are not available.

For deeper dives on this peptide, see:

• PEG-MGF benefits and areas of interest
• PEG-MGF side effects and safety context
• PEG-MGF dosing concepts (educational)
• PEG-MGF research and evidence overview

What does PEGylation actually do? Attaching one or more polyethylene glycol chains to a peptide makes the molecule physically larger and more water-soluble, which slows its removal by the kidney and shields it from degrading enzymes, giving a longer residence time in the body and often reduced immunogenicity (Veronese & Pasut, Drug Discov Today 2005). It is a well-established technique used in approved medicines. What it does not do is change what the underlying peptide is capable of.

Is there any human data on PEG-MGF? None. No interventional clinical trial administering PEG-MGF — or unmodified MGF — to people is registered on ClinicalTrials.gov. There is no published human pharmacokinetic study, no dose-ranging work, and no safety database. Every figure circulating in performance forums is extrapolation from animal and cell work, or from nothing at all.

Does the longer half-life make PEG-MGF better than MGF? Only if the peptide works, and that is the unresolved question. When two pharmaceutical companies attempted to reproduce the published effects of MGF peptide, neither the native peptide nor a stabilised version increased myoblast proliferation, delayed fusion, affected primary muscle stem cells, or activated p-ERK in cardiac myocytes — while IGF-1 did all of these in the same experiments (Fornaro et al., Am J Physiol Endocrinol Metab 2014). Extending the half-life of a peptide whose activity has not replicated extends exposure, not effect.

How does PEG-MGF relate to IGF-1? IGF-1 is the mature, 70-amino-acid growth factor, approved as the medicine mecasermin. MGF is the 24-residue tail discarded when IGF-1 is cut out of its precursor, and PEG-MGF is that tail with a PEG chain attached. Evidence for the E-peptide's independent activity is weak: its signalling effects were abolished by blocking the IGF-1 receptor, suggesting it modulates IGF-1 rather than acting on its own (Brisson & Barton, PLoS One 2012).

Is PEG-MGF prohibited in sport? Yes. The 2026 Prohibited List names "Mechano growth factors (MGFs)" under S2.3, growth factors and growth factor modulators, prohibited at all times and non-Specified — a four-year default sanction (WADA Prohibited List). PEGylation is a chemical modification of a listed substance, not an exit from the list, and S2 explicitly extends to substances with similar chemical structure or similar biological effect.

Why is this compound not in clinical development? Because the underlying biology did not survive scrutiny. IGF-1 signalling remains an active therapeutic area, but the specific hypothesis that the discarded E-peptide is a distinct muscle-repair hormone lost support once independent groups tested it. Investigational compounds usually stall for boring reasons — a failed replication is one of the most common.